<DOC>
	<DOCNO>NCT00619645</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , fludarabine busulfan , donor peripheral stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study side effect give donor peripheral stem cell transplant together fludarabine busulfan see well work treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant , Fludarabine , Busulfan Treating Patients With Hematologic Cancers</brief_title>
	<detailed_description>OBJECTIVES : - To assess efficacy toxicity reduced-intensity allogeneic peripheral blood stem cell transplantation patient hematological malignancy treat condition therapy comprise fludarabine phosphate busulfan . - To evaluate progression-free survival overall survival patient treat regimen . - To determine donor chimerism . - To access risk acute chronic graft-versus-host-disease ( GVHD ) patient treat regimen . OUTLINE : - Conditioning regimen : Patients receive busulfan IV 3 hour day -6 -5 fludarabine phosphate IV 30 minute day -6 -2 . - Allogeneic peripheral blood stem cell transplant ( PBSC ) : Patients undergo allogeneic PBSC day 0 . - Immunosuppressive therapy/graft-versus-host disease ( GVHD ) prophylaxis : Patients achieve100 % donor T-cell chimerism day 30 without disease recurrence , cyclosporine A ( CSA ) IV continuously 24 hour orally every 12 hour day -1 60 followed taper day 100 oral mycophenolate mofetil ( MMF ) every 12 hour day 1-40 , absence ≥ grade 2 GVHD . Patients recurrent disease &lt; 100 % donor T-cell chimerism ( day 30 ) undergo 12-day CSA MMF taper follow escalating dos previously collect donor leukocyte infusion every 4 week 100 % donor T-cell chimerism disease regression , absence ≥ grade 2 GVHD . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed follow : Acute myeloid leukemia ( AML ) , meet 1 follow criterion : Recurrent disease remission , define morphological remission bone marrow aspirate/biopsy show ≤ 5 % within 4 week start study treatment ( cytogenetic molecular remission require ) In first complete remission ( CR1 ) poorrisk cytogenetics , antecedent hematological disease ( i.e. , myelodysplasia ) , treatmentrelated leukemia Acute lymphoblastic leukemia ( ALL ) , meet 1 follow criterion : Recurrent disease remission , define morphological remission bone marrow aspirate/biopsy show ≤ 5 % within 4 week start study treatment ( cytogenetic molecular remission require ) CR1 Philadelphia chromosome poorrisk cytogenetics Chronic myelogenous leukemia ( CML ) , meet follow criterion : First second chronic phase Must document disease progression imatinib mesylate therapy OR document lack cytogenetic response 6 month postimatinib mesylate initiation OR imatinib mesylate intolerance Chronic lymphocytic leukemia ( CLL ) , meet follow criterion : Recurrent disease fludarabinebased therapy Must chemosensitive disease time relapse , define great 50 % reduction WBC lymphadenopathy Recurrent Hodgkin lymphoma , recurrent nonHodgkin lymphoma ( NHL ) ( low , intermediate , highgrade disease* ) , transform NHL , meet 1 follow criterion : Received prior autologous transplantation cytoreductive therapy time relapse achieve complete remission ( CR ) CR/unconfirmed ( CRu ) define International Workshop Relapsed disease require 2 salvage regimen achieve CR CRu Recurrent multiple myeloma , meet follow criterion : Must receive prior autologous transplantation demonstrate chemosensitivity time relapse , define great 50 % reduction Mcomponent plasmacell marrow infiltration Myelodysplastic syndrome Refractory anemia ( RA ) /RA ring sideroblast ( RARS ) , refractory cytopenia multilineage dysplasia ( RCMD ) /refractory cytopenia multilineage dysplasia ring sideroblast ( RCMDRS ) , RA excess blast ( RAEB ) I , meet follow criterion : Must transfusiondependent IPSS score ≥ 1.5 , base WHO criteria No RAEB II del ( 5q ) No uncontrolled CNS metastases 56/6 HLAmatched sibling 910/10 match unrelated donor ( patient donor ) available NOTE : *A new classification scheme adult nonHodgkin lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 50 % Serum creatinine ≤ 2 mg/dL Not pregnant Fertile patient must use effective contraception 50 year age old Patients 1850 year age eligible meeting 1 follow criterion : Have preexist medical condition Received prior therapy ( i.e. , autologous transplantation ) consider high risk conventional myeloablative transplantation Must willing accept comprehend irreversible sterility side effect therapy No uncontrolled active infection No psychiatric illness mental deficiency make compliance treatment inform consent impossible Cardiac ejection fraction ≥ 30 % Corrected pulmonarydiffusing capacity ≥ 35 % No serologic evidence infection HIV No decompensated liver disease serum bilirubin &gt; 2.0 mg/dL PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>